<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Microsatellite instability (MSI) testing is used to screen for <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The current technique for MSI determination requires DNA from <z:mpath ids='MPATH_458'>normal</z:mpath> and neoplastic tissue and is expensive and laborious </plain></SENT>
<SENT sid="2" pm="."><plain>Five quasi-monomorphic markers (NR-21, BAT-25, MONO-27, NR-24, and BAT-26) are included in the Promega MSI analysis kit </plain></SENT>
<SENT sid="3" pm="."><plain>With the working hypothesis that this 5-marker panel can accurately determine the MSI status of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> without using paired control DNA, we evaluated 478 colorectal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and divided them into a test group (N=172, colorectal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>) and a validation group (N=306 including 179 colorectal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and 127 <z:mpath ids='MPATH_270'>adenomas</z:mpath>) </plain></SENT>
<SENT sid="4" pm="."><plain>The quasi-monomorphic variation range of each marker was generated from the test group (172 <z:mpath ids='MPATH_458'>normal</z:mpath> samples) and used as a reference value in the subsequent interpretation of MSI status in the test and validation groups </plain></SENT>
<SENT sid="5" pm="."><plain>Considering the MSI result using a 5-marker panel with paired control DNA as the gold standard, we identified 136 microsatellite stable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>) and 36 microsatellite instability-high (MSI-H) <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> in the test group and 259 MSS and 47 MSI-H <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> in the validation group </plain></SENT>
<SENT sid="6" pm="."><plain>Using the quasi-monomorphic variation range of each marker rather than paired <z:mpath ids='MPATH_458'>normal</z:mpath> DNA, the 5-marker panel identified <z:hpo ids='HP_0000001'>all</z:hpo> MSI-H <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> in the test and validation groups, when MSI-H was defined as â‰¥2 unstable markers </plain></SENT>
<SENT sid="7" pm="."><plain>Our study demonstrates that the 5-marker panel within a multiplex polymerase chain reaction of the Promega MSI analysis kit accurately identifies <z:hpo ids='HP_0000001'>all</z:hpo> MSI-H and 95.2% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e> <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> without using paired <z:mpath ids='MPATH_458'>normal</z:mpath> DNA </plain></SENT>
</text></document>